Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products worldwide. The last earnings update was 88 days ago. More info.
Add to Portfolio Compare Print
- Mayne Pharma Group has significant price volatility in the past 3 months.
MYX Share Price and Events
7 Day Returns
1 Year Returns
MYX Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Mayne Pharma Group (MYX) | -13.5% | -12.9% | -29.9% | -21.8% | -61.4% | -39.2% |
| AU Pharmaceuticals | -1.8% | -5.5% | -4.2% | -27.9% | -36.3% | -25.6% |
| AU Market | 1.1% | 1.6% | 4.1% | 2.6% | 17.9% | 7.7% |
1 Year Return vs Industry and Market
- MYX outperformed the Pharmaceuticals industry which returned -27.9% over the past year.
- MYX underperformed the Market in Australia which returned 2.6% over the past year.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Mayne Pharma Group
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Mayne Pharma Group.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 6 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 7.9% |
| Perpetual Growth Rate | 10-Year AU Government Bond Rate | 2.3% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year AU Govt Bond Rate | 2.3% |
| Equity Risk Premium | S&P Global | 6% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 0.69 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.695 (1 + (1- 30%) (42.62%)) |
0.934 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.93 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (0.934 * 5.96%) |
7.88% |
Discounted Cash Flow Calculation for ASX:MYX using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Mayne Pharma Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (AUD, Millions) | Source |
Present Value Discounted (@ 7.88%) |
|
|---|---|---|---|
| 2019 | 112.00 | Analyst x1 | 103.82 |
| 2020 | 73.70 | Analyst x2 | 63.33 |
| 2021 | 102.90 | Analyst x1 | 81.96 |
| 2022 | 127.45 | Est @ 23.86% | 94.09 |
| 2023 | 149.62 | Est @ 17.39% | 102.39 |
| 2024 | 168.87 | Est @ 12.87% | 107.13 |
| 2025 | 185.26 | Est @ 9.7% | 108.94 |
| 2026 | 199.12 | Est @ 7.49% | 108.54 |
| 2027 | 210.94 | Est @ 5.93% | 106.58 |
| 2028 | 221.16 | Est @ 4.85% | 103.58 |
| Present value of next 10 years cash flows | A$980.34 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= A$221.16 × (1 + 2.31%) ÷ (7.88% – 2.31%) |
A$4,063.40 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= A$4,063.40 ÷ (1 + 7.88%)10 |
A$1,903.08 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= A$980.34 + A$1,903.08 |
A$2,883.42 |
| Equity Value per Share (AUD) |
= Total value / Shares Outstanding
= A$2,883.42 / 1,582.94 |
A$1.82 |
| Calculation | Result | |
|---|---|---|
| Value per share (AUD) | From above. | A$1.82 |
| Current discount | Discount to share price of
A$0.58
= -1 x (A$0.58 - A$1.82) / A$1.82 |
68.4% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Mayne Pharma Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Mayne Pharma Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Mayne Pharma Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Mayne Pharma Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in AUD | A$0.03 |
| ASX:MYX Share Price ** | ASX (2019-05-20) in AUD | A$0.58 |
| Australia Pharmaceuticals Industry PE Ratio | Median Figure of 6 Publicly-Listed Pharmaceuticals Companies | 19.76x |
| Australia Market PE Ratio | Median Figure of 542 Publicly-Listed Companies | 15.99x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Mayne Pharma Group.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ASX:MYX Share Price ÷ EPS (both in AUD) = 0.58 ÷ 0.03 |
18.48x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Mayne Pharma Group is good value based on earnings compared to the AU Pharmaceuticals industry average.
- Mayne Pharma Group is overvalued based on earnings compared to the Australia market.
Price based on expected Growth
Does
Mayne Pharma Group's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | 18.48x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts |
37%per year |
| Global Pharmaceuticals Industry PEG Ratio | Median Figure of 118 Publicly-Listed Pharmaceuticals Companies | 1.56x |
| Australia Market PEG Ratio | Median Figure of 359 Publicly-Listed Companies | 1.44x |
*Line of best fit is calculated by linear regression .
| Calculation | Outcome | |
|---|---|---|
| PEG Ratio | = PE Ratio ÷ Net Income Annual Growth Rate = 18.48x ÷ 37% |
0.5x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Mayne Pharma Group is good value based on expected growth next year.
Price based on value of assets
What value do investors place on
Mayne Pharma Group's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in AUD | A$0.81 |
| ASX:MYX Share Price * | ASX (2019-05-20) in AUD | A$0.58 |
| Australia Pharmaceuticals Industry PB Ratio | Median Figure of 26 Publicly-Listed Pharmaceuticals Companies | 3.44x |
| Australia Market PB Ratio | Median Figure of 1,676 Publicly-Listed Companies | 1.65x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ASX:MYX Share Price ÷ Book Value per Share (both in AUD) = 0.58 ÷ 0.81 |
0.71x |
* Primary Listing of Mayne Pharma Group.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Mayne Pharma Group is good value based on assets compared to the AU Pharmaceuticals industry average.
Value checks
We assess Mayne Pharma Group's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Mayne Pharma Group has a total score of 5/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Mayne Pharma Group's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
- Mayne Pharma Group's earnings growth is expected to exceed the Australia market average.
- Mayne Pharma Group's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ASX:MYX Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts | 37% |
| ASX:MYX Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts | 10.6% |
| Australia Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 51.4% |
| Australia Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 32.2% |
| Australia Market Earnings Growth Rate | Market Cap Weighted Average | 6.9% |
| Australia Market Revenue Growth Rate | Market Cap Weighted Average | 3.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-06-30 | 666 | 142 | 75 | 5 |
| 2020-06-30 | 575 | 123 | 48 | 6 |
| 2019-06-30 | 525 | 138 | 25 | 6 |
| Date (Data in AUD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 561 | 127 | 43 |
| 2018-09-30 | 546 | 124 | -46 |
| 2018-06-30 | 530 | 121 | -134 |
| 2018-03-31 | 526 | 111 | -146 |
| 2017-12-31 | 521 | 100 | -158 |
| 2017-09-30 | 547 | 42 | -35 |
| 2017-06-30 | 573 | -15 | 89 |
| 2017-03-31 | 504 | -30 | 90 |
| 2016-12-31 | 435 | -44 | 91 |
| 2016-09-30 | 351 | 5 | 64 |
| 2016-06-30 | 267 | 54 | 37 |
| 2016-03-31 | 238 | 49 | 30 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (4 months ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
All data from Mayne Pharma Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-06-30 | 0.04 | 0.05 | 0.03 | 4.00 |
| 2020-06-30 | 0.03 | 0.04 | 0.02 | 5.00 |
| 2019-06-30 | 0.01 | 0.02 | 0.00 | 3.00 |
| Date (Data in AUD Millions) | EPS * |
|---|---|
| 2018-12-31 | 0.03 |
| 2018-09-30 | -0.03 |
| 2018-06-30 | -0.09 |
| 2018-03-31 | -0.10 |
| 2017-12-31 | -0.11 |
| 2017-09-30 | -0.02 |
| 2017-06-30 | 0.06 |
| 2017-03-31 | 0.07 |
| 2016-12-31 | 0.08 |
| 2016-09-30 | 0.07 |
| 2016-06-30 | 0.05 |
| 2016-03-31 | 0.04 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Mayne Pharma Group's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Mayne Pharma Group has a total score of 4/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Mayne Pharma Group performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Mayne Pharma Group's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Mayne Pharma Group has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
- Mayne Pharma Group has become profitable in the last year making it difficult to compare the Global Pharmaceuticals industry average.
Earnings and Revenue History
All data from Mayne Pharma Group Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in AUD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 561.43 | 42.80 | 226.03 | 19.37 |
| 2018-09-30 | 545.87 | -45.59 | 213.32 | 15.84 |
| 2018-06-30 | 530.31 | -133.98 | 200.61 | 12.30 |
| 2018-03-31 | 525.67 | -146.18 | 197.47 | 10.03 |
| 2017-12-31 | 521.02 | -158.38 | 194.33 | 7.77 |
| 2017-09-30 | 546.81 | -34.90 | 192.40 | 8.02 |
| 2017-06-30 | 572.60 | 88.57 | 190.48 | 8.28 |
| 2017-03-31 | 503.72 | 89.71 | 173.44 | 8.02 |
| 2016-12-31 | 434.85 | 90.86 | 156.40 | 7.76 |
| 2016-09-30 | 351.07 | 64.11 | 135.95 | 7.39 |
| 2016-06-30 | 267.28 | 37.36 | 115.50 | 7.03 |
| 2016-03-31 | 238.21 | 30.18 | 104.51 | 6.91 |
| 2015-12-31 | 209.13 | 23.00 | 93.53 | 6.79 |
| 2015-09-30 | 175.28 | 15.38 | 76.89 | 5.55 |
| 2015-06-30 | 141.42 | 7.76 | 60.25 | 4.31 |
| 2015-03-31 | 137.13 | 12.31 | 50.06 | 3.50 |
| 2014-12-31 | 132.85 | 16.85 | 39.87 | 2.68 |
| 2014-09-30 | 138.05 | 19.07 | 37.32 | 3.62 |
| 2014-06-30 | 143.25 | 21.29 | 34.78 | 4.55 |
| 2014-03-31 | 134.73 | 14.71 | 32.86 | 5.36 |
| 2013-12-31 | 126.21 | 8.13 | 30.95 | 6.16 |
| 2013-09-30 | 104.82 | 2.64 | 25.24 | 5.07 |
| 2013-06-30 | 83.43 | -2.84 | 19.53 | 3.99 |
| 2013-03-31 | 67.85 | -1.56 | 14.63 | 3.77 |
| 2012-12-31 | 52.26 | -0.27 | 9.73 | 3.56 |
| 2012-09-30 | 52.24 | 2.94 | 9.14 | 3.79 |
| 2012-06-30 | 52.21 | 6.15 | 8.55 | 4.02 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- Mayne Pharma Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Mayne Pharma Group used its assets less efficiently than the AU Pharmaceuticals industry average last year based on Return on Assets.
- Mayne Pharma Group's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
Past performance checks
We assess Mayne Pharma Group's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Mayne Pharma Group has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Mayne Pharma Group's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Mayne Pharma Group's finances.
The net worth of a company is the difference between its assets and liabilities.
- Mayne Pharma Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Mayne Pharma Group's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Mayne Pharma Group Company Filings, last reported 4 months ago.
| Date (Data in AUD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 1,297.41 | 394.62 | 100.16 |
| 2018-09-30 | 1,297.41 | 394.62 | 100.16 |
| 2018-06-30 | 1,235.16 | 374.19 | 102.38 |
| 2018-03-31 | 1,235.16 | 374.19 | 102.38 |
| 2017-12-31 | 1,133.14 | 359.09 | 65.07 |
| 2017-09-30 | 1,133.14 | 359.09 | 65.07 |
| 2017-06-30 | 1,312.42 | 340.25 | 70.65 |
| 2017-03-31 | 1,312.42 | 340.25 | 70.65 |
| 2016-12-31 | 1,370.66 | 313.45 | 85.89 |
| 2016-09-30 | 1,370.66 | 313.45 | 85.89 |
| 2016-06-30 | 376.22 | 76.83 | 50.40 |
| 2016-03-31 | 376.22 | 76.83 | 50.40 |
| 2015-12-31 | 352.15 | 64.80 | 51.39 |
| 2015-09-30 | 352.15 | 64.80 | 51.39 |
| 2015-06-30 | 322.20 | 61.76 | 60.47 |
| 2015-03-31 | 322.20 | 61.76 | 60.47 |
| 2014-12-31 | 180.00 | 58.88 | 19.88 |
| 2014-09-30 | 180.00 | 58.88 | 19.88 |
| 2014-06-30 | 159.27 | 48.03 | 15.21 |
| 2014-03-31 | 159.27 | 48.03 | 15.21 |
| 2013-12-31 | 133.80 | 55.53 | 20.12 |
| 2013-09-30 | 133.80 | 55.53 | 20.12 |
| 2013-06-30 | 120.89 | 46.70 | 18.94 |
| 2013-03-31 | 120.89 | 46.70 | 18.94 |
| 2012-12-31 | 107.16 | 41.92 | 30.70 |
| 2012-09-30 | 107.16 | 41.92 | 30.70 |
| 2012-06-30 | 30.60 | 0.00 | 11.60 |
- Mayne Pharma Group's level of debt (30.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (41.4% vs 30.4% today).
- Debt is well covered by operating cash flow (32.2%, greater than 20% of total debt).
- Interest payments on debt are well covered by earnings (EBIT is 6.1x coverage).
Financial health checks
We assess Mayne Pharma Group's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Mayne Pharma Group has a total score of 6/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Mayne Pharma Group's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
A$2,000 of
Mayne Pharma Group
shares you are expected to receive
A$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Mayne Pharma Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Mayne Pharma Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| Global Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 143 Stocks | 3% |
| Australia Market Average Dividend Yield | Market Cap Weighted Average of 415 Stocks | 4.3% |
| Australia Minimum Threshold Dividend Yield | 10th Percentile | 1.5% |
| Australia Bottom 25% Dividend Yield | 25th Percentile | 2.6% |
| Australia Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in A$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-06-30 | 0.00 | 5.00 |
| 2020-06-30 | 0.00 | 5.00 |
| 2019-06-30 | 0.00 | 5.00 |
| Date (Data in A$) | Dividend per share (annual) | Avg. Yield (%) |
|---|---|---|
| 2012-02-28 | 0.000 | 0.000 |
| 2011-09-13 | 0.000 | 0.000 |
| 2011-08-31 | 0.000 | 0.000 |
| 2010-09-29 | 0.020 | 3.503 |
| 2010-08-31 | 0.020 | 3.583 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Mayne Pharma Group has not reported any payouts.
- Unable to verify if Mayne Pharma Group's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Mayne Pharma Group's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Mayne Pharma Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Mayne Pharma Group has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | A$2,509,025 |
| AGE | 54 |
| TENURE AS CEO | 7.3 years |
CEO Bio
Mr. Scott Anthony Richards has been the Chief Executive Officer and Managing Director of Mayne Pharma Group Limited since February 13, 2012. Mr. Richards joined Mayne Pharma in February 2012. He served as the President, European Operations of Intas Pharmaceutical Limited. He served as an Executive at Intas Pharmaceuticals Ltd since October 06, 2011. He served as President of European Operations & Global Hospital Business at Accord Healthcare (Uk) Limited. He spent ten years in Europe in a variety of leadership roles including President, Europe, Middle East and Africa and President, Global Commercial Operations for Mayne Pharma Limited. He led Mayne Pharma's EMEA and Asia Pacific operations. Prior to working in Europe, he spent 14 years with FH Faulding and Co in a variety of roles including leading Faulding Pharmaceuticals Asia Pacific operations together with spending five years with Faulding in the United States leading business development and portfolio management operations. He joined Actavis in June 2006. Mr. Richards was also Executive Vice President at Actavis Group responsible for the Hospital Business Operations worldwide. Mr. Richards served as President of Europe Middle East Africa at Idameneo (No.789) Ltd. Mr. Richards served as President of Accord Healthcare Inc. He served as the President of Global Commercial Operations at Hospira Australia Pty Ltd. He served as the President for Europe, Middle East, Africa of Mayne Group Ltd. Mr. Richards joined Mayne in 2001. He has more than 28 years' international experience in the pharmaceutical industry and has worked in Europe, the US and Asia. His experience spans sales and marketing, regulatory/medical affairs, supply chain, business development, mergers and acquisitions, finance, intellectual property and manufacturing. Mr. Richards held a number of senior positions in Faulding's pharmaceutical business, including Vice President of Commercial Operations for Australia and New Zealand. He was Executive Vice President of Global Hospital Business at Actavis LLC. He was Executive Vice President of Global Hospital Business at Actavis Group hf. He also served on the Group Management Board of Actavis for 4 years where he was responsible for its global injectable/hospital business operations. Mr. Richards has been an Executive Director at Mayne Pharma Group Limited since February 13, 2012. He studied Medicine and Economics degrees in Australia.
CEO Compensation
- Scott's compensation has been consistent with company performance over the past year, both up more than 20%.
- Scott's remuneration is higher than average for companies of similar size in Australia.
Management Team Tenure
Average tenure of the Mayne Pharma Group management team in years:
- The tenure for the Mayne Pharma Group management team is about average.
Management Team
Scott Richards
MD, CEO & Executive Director
A$3M
54
7.3 yrs
Nick Freeman
Group CFO & Company Secretary
A$863K
2 yrs
Stefan Cross
President of International Operations
A$1M
45
2.3 yrs
Ilana Stancovski
Chief Scientific Officer & Head of European Market Development
A$1M
4.7 yrs
Lisa Pendlebury
Vice President of Investor Relations & Communications
A$580K
3.5 yrs
Kate Rintoul
Executive VP & General Counsel
A$932K
6.3 yrs
Peter Paltoglou
Chief Development Officer & Head of M&A
A$1M
3.8 yrs
John Ross
President of Mayne Pharma USA
A$2M
2.3 yrs
Andy Herdman
Vice President of Group Human Resources
0.7 yrs
Gadi Ben-Nissim
Executive Vice President of Generic Products
2.3 yrs
Board of Directors Tenure
Average tenure and age of the Mayne Pharma Group board of directors in years:
- The tenure for the Mayne Pharma Group board of directors is about average.
Board of Directors
Roger Corbett
Independent Chairman
A$289K
75
8.3 yrs
Scott Richards
MD, CEO & Executive Director
A$3M
54
7.3 yrs
Ron Best
Independent Non Executive Director
A$142K
12.8 yrs
Ian Scholes
Independent Non-Executive Director
A$153K
63
11.6 yrs
Bruce Robinson
Independent Non-Executive Director
A$131K
61
4.8 yrs
Bruce Mathieson
Independent Non Executive Director
A$123K
12.3 yrs
Nancy Dolan
Independent Non-Executive Director
A$151K
2.7 yrs
Frank Condella
Independent Non-Executive Director
A$11K
64
1 yrs
Pat Blake
Independent Non-Executive Director
54
0.9 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (A$) | Value (A$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 13. Mar 19 | Sell | Investors Mutual Limited | Company | 09. Oct 18 | 30. Oct 18 | -10,493,059 | A$1.19 | A$-12,519,923 | ||
| 13. Mar 19 | Buy | Investors Mutual Limited | Company | 29. Nov 18 | 12. Mar 19 | 27,381,071 | A$0.81 | A$22,211,021 | ||
| 31. Dec 18 | Buy | Nancy Dolan | Individual | 21. Dec 18 | 21. Dec 18 | 27,272 | A$0.78 | A$21,173 | ||
| 24. Dec 18 | Buy | Frank Condella | Individual | 21. Dec 18 | 24. Dec 18 | 181,835 | A$0.77 | A$139,334 | ||
| 14. Dec 18 | Sell | Vinva Investment Management | Company | 05. Dec 18 | 12. Dec 18 | -106,864 | A$0.91 | A$-97,125 | ||
| 14. Dec 18 | Buy | Vinva Investment Management | Company | 05. Dec 18 | 12. Dec 18 | 103,279 | A$0.95 | A$97,630 | ||
| 06. Dec 18 | Sell | Vinva Investment Management | Company | 04. Aug 18 | 04. Dec 18 | -165,726 | A$1.16 | A$-192,671 | ||
| 06. Dec 18 | Buy | Vinva Investment Management | Company | 04. Aug 18 | 04. Dec 18 | 99,648,311 | A$1.17 | A$116,410,354 | ||
| 07. Jun 18 | Sell | Lazard Asset Management LLC | Company | 05. Mar 18 | 05. Jun 18 | -11,617,848 | A$0.87 | A$-9,722,235 | ||
Management checks
We assess Mayne Pharma Group's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Mayne Pharma Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Does Mayne Pharma Group Limited's (ASX:MYX) CEO Salary Compare Well With Others?
Check out our latest analysis for Mayne Pharma Group How Does Scott Richards's Compensation Compare With Similar Sized Companies? … According to our data, Mayne Pharma Group Limited has a market capitalization of AU$879m, and pays its CEO total annual compensation worth AU$2.5m. … We examined the amount Mayne Pharma Group Limited pays its CEO, and compared it to the amount paid by similar sized companies.
Simply Wall St - – Full articleIs Mayne Pharma Group Limited's (ASX:MYX) ROE Of 3.1% Concerning?
We'll use ROE to examine Mayne Pharma Group Limited (ASX:MYX), by way of a worked example. … Over the last twelve months Mayne Pharma Group has recorded a ROE of 3.1%. … That means that for every A$1 worth of shareholders' equity, it generated A$0.031 in profit.
Simply Wall St - – Full articleCould The Mayne Pharma Group Limited (ASX:MYX) Ownership Structure Tell Us Something Useful?
If you want to know who really controls Mayne Pharma Group Limited (ASX:MYX), then you'll have to look at the makeup of its share registry. … Generally speaking, as a company grows, institutions will increase their ownership. … Mayne Pharma Group is a smaller company with a market capitalization of AU$1.1b, so it may still be flying under the radar of many institutional investors.
Simply Wall St - – Full articleDid You Manage To Avoid Mayne Pharma Group's (ASX:MYX) Painful 52% Share Price Drop?
Unfortunately, that's been the case for longer term Mayne Pharma Group Limited (ASX:MYX) shareholders, since the share price is down 52% in the last three years, falling well short of the market return of around 41%. … View our latest analysis for Mayne Pharma Group. … One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.
Simply Wall St - – Full articleWhy Fundamental Investors Might Love Mayne Pharma Group Limited (ASX:MYX)
Want to participate in a short research study? … Help shape the future of investing tools and receive a $20 prize! … In the case of Mayne Pharma Group Limited (ASX:MYX), there's
Simply Wall St - – Full articleHow Should Investors Feel About Mayne Pharma Group Limited's (ASX:MYX) CEO Pay?
In 2012 Scott Richards was appointed CEO of Mayne Pharma Group Limited (ASX:MYX). … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Scott Richards's Compensation Compare With Similar Sized Companies?
Simply Wall St - – Full articleMayne Pharma Group Limited (ASX:MYX): What Does Its Beta Value Mean For Your Portfolio?
Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.
Simply Wall St - – Full articleShould You Be Worried About Insider Transactions At Mayne Pharma Group Limited (ASX:MYX)?
So before you buy or sell Mayne Pharma Group Limited (ASX:MYX), you may well want to know whether insiders have been buying or selling. … The Last 12 Months Of Insider Transactions At Mayne Pharma Group. … That means that an insider was selling shares at below the current price (AU$0.92).
Simply Wall St - – Full articleIs Mayne Pharma Group Limited's (ASX:MYX) Balance Sheet A Threat To Its Future?
Mayne Pharma Group Limited (ASX:MYX) is a small-cap stock with a market capitalization of AU$1.6b. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is
Simply Wall St - – Full articleHow Much is Mayne Pharma Group Limited's (ASX:MYX) CEO Getting Paid?
First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Scott Richards's Compensation Compare With Similar Sized Companies. … Our data indicates that Mayne Pharma Group Limited is worth AU$1.7b, and total annual CEO compensation is AU$3m.
Simply Wall St - – Full articleCompany Info
Description
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products worldwide. It operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. The company also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited is based in Salisbury South, Australia.
Details
| Name: | Mayne Pharma Group Limited |
| MYX | |
| Exchange: | ASX |
| Founded: | |
| A$926,017,864 | |
| 1,582,936,521 | |
| Website: | http://www.maynepharma.com |
| Address: |
Mayne Pharma Group Limited 1538 Main North Road, Salisbury South, South Australia, 5106, Australia |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ASX | MYX | Ordinary Shares | Australian Securities Exchange | AU | AUD | 29. Jun 2007 | |
| OTCPK | MAYN.F | Ordinary Shares | Pink Sheets LLC | US | USD | 29. Jun 2007 | |
| DB | HG6 | Ordinary Shares | Deutsche Boerse AG | DE | EUR | 29. Jun 2007 | |
| CHIA | MYX | Ordinary Shares | Chi-X Australia | AU | AUD | 29. Jun 2007 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/05/20 10:34 |
| End of day share price update: | 2019/05/20 00:00 |
| Last estimates confirmation: | 2019/05/15 |
| Last earnings filing: | 2019/02/21 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
